Stay updated
with us
Medicines360 is constantly evolving, and we want to keep you informed about our latest projects, partnerships, and achievements.
News
Learn more about significant announcements and developments at Medicines360 and the impact we are making in the field of women’s health.
-
FDA Approves Medicines360’s Supplemental New Drug Application for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg as Treatment of Heavy Menstrual Bleeding
-
Medicines360 Appoints Andrea Olariu, MD, PhD as Chief Executive Officer
-
Medicines360 Applauds U.S. Congress for Enshrining Nonprofit Pharma in Federal Law for the First Time
-
FDA Approves Medicines360’s LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Eight Years
-
Medicines360 Calls on U.S. Congress to Pass Affordability is Access Act Without Delay
-
Defying Definitions and Breaking Down Barriers: Lessons from Medicines360’s Nonprofit Journey
